Kaye S - Search Results

1

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.

Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: kaye s. J Clin Oncol. 2009 Jun 1;27(16):2692-6. doi: 10.1200/JCO.2008.19.5081. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332724

2

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: kaye s. Eur J Cancer. 2008 Jul;44(11):1536-40. doi: 10.1016/j.ejca.2008.04.017. Epub 2008 Jun 10. Eur J Cancer. 2008. PMID: 18550361

3

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.

Arkenau HT, Brunetto AT, Barriuso J, Olmos D, Eaton D, de Bono J, Judson I, Kaye S. Arkenau HT, et al. Among authors: kaye s. Oncology. 2009;76(3):151-6. doi: 10.1159/000195884. Epub 2009 Jan 23. Oncology. 2009. PMID: 19169046

4

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, de Bono J, Judson I, Kaye S. Brunetto AT, et al. Among authors: kaye s. Eur J Cancer. 2010 Oct;46(15):2739-45. doi: 10.1016/j.ejca.2010.06.123. Epub 2010 Aug 11. Eur J Cancer. 2010. PMID: 20667711

5

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X. Postel-Vinay S, et al. Among authors: kaye s. J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444876

6

Perceptions and referral trends into phase I oncology trials: results of a clinical survey.

Brunetto A, Olmos D, Arkenau HT, Tan D, Yap T, de Bono J, Barriuso J, Kaye S. Brunetto A, et al. Among authors: kaye s. J Oncol. 2011;2011:861401. doi: 10.1155/2011/861401. Epub 2011 Jun 27. J Oncol. 2011. PMID: 21772849 Free PMC article.

7

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Attard G, et al. Among authors: kaye sb. J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470933 Free PMC article. Clinical Trial.

8

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. Yap TA, et al. Among authors: kaye sb. J Clin Oncol. 2011 Apr 1;29(10):1271-9. doi: 10.1200/JCO.2010.31.0367. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383285 Clinical Trial.

9

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS. Olmos D, et al. Among authors: kaye sb. Clin Cancer Res. 2011 Aug 1;17(15):5188-96. doi: 10.1158/1078-0432.CCR-10-3019. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531820

10

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Olmos D, et al. Among authors: kaye sb. J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355064

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,501 results

Search Page

Filters